Hepatitis C Virus Infection in Pregnancy

Altınbaş, Şadıman Kıykaç; Holmes, Jacinta A; Altınbaş, Akif

doi:10.1097/sga.0000000000000404

Cited by 19 publications

(23 citation statements)

References 74 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Administration of high doses of ribavirin in SARS trials was associated with serious adverse reactions including haemolytic anaemia, electrolyte disturbances and significant teratogenicity. [ 88 , 130 , 131 ]. Given its considerable adverse effect profile, toxicity and the lack of in vitro data evaluating the efficacy of this compound, the administration of ribavirin for the treatment of COVID-19 is not recommended.…”

Section: Available Treatment Options For Covid-19mentioning

confidence: 99%

COVID-19: The Immune Responses and Clinical Therapy Candidates

Zhand

Jazi

Mohammadi

et al. 2020

IJMS

View full text Add to dashboard Cite

The pandemic of coronavirus disease 2019 (COVID-19), with rising numbers of patients worldwide, presents an urgent need for effective treatments. To date, there are no therapies or vaccines that are proven to be effective against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Several potential candidates or repurposed drugs are under investigation, including drugs that inhibit SARS-CoV-2 replication and block infection. The most promising therapy to date is remdesivir, which is US Food and Drug Administration (FDA) approved for emergency use in adults and children hospitalized with severe suspected or laboratory-confirmed COVID-19. Herein we summarize the general features of SARS-CoV-2’s molecular and immune pathogenesis and discuss available pharmacological strategies, based on our present understanding of SARS-CoV and Middle East respiratory syndrome coronavirus (MERS-CoV) infections. Finally, we outline clinical trials currently in progress to investigate the efficacy of potential therapies for COVID-19.

show abstract

Section: Available Treatment Options For Covid-19mentioning

confidence: 99%

COVID-19: The Immune Responses and Clinical Therapy Candidates

Zhand

Jazi

Mohammadi

et al. 2020

IJMS

View full text Add to dashboard Cite

show abstract

“…However, its clinical efficacy may be improved with combination therapy. Ribavirin is also a known teratogen and contraindicated in pregnancy (79) . SARS-CoV infections induced a disproportionate immune response.…”

Section: Treatment Of Sars-cov-2mentioning

confidence: 99%

Genetic Structure, Transmission, Clinical Characteristics, Diagnosis, Treatment and Prevention of Coronavirus Disease 2019 (COVID-19): A Review

Al-Mayyahi

Al-Tumah

2021

IJPS

View full text Add to dashboard Cite

The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused a pandemic of coronavirus disease 2019 (COVID-19) which represents a global public health crisis. Based on recent published studies, this review discusses current evidence related to the transmission, clinical characteristics, diagnosis, management and prevention of COVID-19. It is hoped that this review article will provide a benefit for the public to well understand and deal with this new virus, and give a reference for future researches.

show abstract

“…Also, ribavirin is contraindicated in pregnancy as it is a known teratogen. Studies suggested that severe doses of ribavirin cause hematologic toxicity, but if used in combination with other drugs it may provide clinical benefits against COVID-19 [36] .…”

Section: Ribavirinmentioning

confidence: 99%

Repurposed drugs and their progression against COVID-19

Rani¹,

Kaur²,

Sen³

et al. 2021

Pharma Innovation

View full text Add to dashboard Cite

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is the causative agent of COVID-19 (Coronavirus disease), which was initially noticed in the seafood market at Wuhan, Hubei Province, China. Since then this deadly virus has outspread like wildfire across the globe and has put all the healthcare services at red alert. The outburst of COVID-19 has already taken the shape of the pandemic, affecting more than 200 countries in just a few months. A global response to prepare our health systems is very much imperative and the whole world is desperate to find ways to tackle this pandemic by developing effective treatments. Unfortunately, no reliable therapeutic interventions are available currently for critically affected ill COVID-19 patients. Treatment of COVID-19 patients is mainly based on symptomatic management. Emerging clinical trials and research data representing the structural and functional aspects of SARS-CoV-2 suggests testing of the repurposed drugs ranging from flu treatments to failed ebola drugs, to anti-malarial drugs that were first developed decades ago. The review focuses on the various already adopted and ongoing trials to date for developing effective therapeutic strategies to combat this viral outbreak. We hope that the accumulated information about various repositioning trials will help the international research community to lead potential clinical practices and to find solutions for COVID-19 treatment in this need of the hour.

show abstract

Hepatitis C Virus Infection in Pregnancy

Cited by 19 publications

References 74 publications

COVID-19: The Immune Responses and Clinical Therapy Candidates

COVID-19: The Immune Responses and Clinical Therapy Candidates

Genetic Structure, Transmission, Clinical Characteristics, Diagnosis, Treatment and Prevention of Coronavirus Disease 2019 (COVID-19): A Review

Repurposed drugs and their progression against COVID-19

Contact Info

Product

Resources

About